TAGRISSO (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth...
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del., August 17, 2026--Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in...
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Aug 17, 2026-- Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO ® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based...
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer.
PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Na PRINCETON, New Jersey, TOKYO, Japan, CAMBRIDGE, Mass., August 12, 2026 - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.,...
Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial
HUTCHMED (China) Ltd HKEX:13: Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial Read the full articleGet unlimited access to articles from Reuters and every other news source on TradingView.Keep reading [Additional Text]: Reuters
Hutchmed (00013): The combination therapy of savolitinib and osimertinib demonstrated statistically and clinically significant improvements in progression-free survival and overall survival in patients with MET-driven EGFR-mutated non-small cell lung canc
Hutchmed(HKEX: 00013) announced that the SAFFRON Phase III study evaluating the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) versus platinum-based doublet chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) has achieved positive top-line results....
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung...
® HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) demonstrated...
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
- First global Phase III trial to show significant progression-free and overall survival benefits in this setting - - SAFFRON trial results reinforce TAGRISSO®as the backbone therapy across EGFRm lung cancer - HONG KONG and SHANGHAI and FLORHAM PARK, N.J.,...